Form 4: Ernexa Therapeutics Director and 10% Owner Significantly Boosts Stake Through Private Placement and Dividend

Charles Cherington, a Director and 10% owner of Ernexa Therapeutics Inc. (ERNA), has substantially increased his beneficial ownership through a private placement and a stock dividend, now holding over 41 million shares.

Summary

• Charles Cherington, a Director and 10% owner of Ernexa Therapeutics Inc. (ERNA), acquired 21,241,163 shares of Common Stock on June 9, 2025, as part of a private placement offering.
• The shares in the private placement were acquired at a price of $0.1046 per share, following stockholder approval.
• Additionally, on June 2, 2025, Mr. Cherington received 16,978 shares of the Issuer's Common Stock as a dividend from his Series A Preferred Stock holdings, where the $0.05 per share dividend was paid in common stock.
• Following these transactions, Charles Cherington's total beneficial ownership in Ernexa Therapeutics Inc. Common Stock stands at 41,659,743 shares.

Sentiment

Score: 8

Explanation: The significant increase in beneficial ownership by a director and 10% owner through a direct investment (private placement) indicates strong insider confidence in the company's future prospects.

Positives

• A key insider, Charles Cherington (Director and 10% owner), significantly increased his stake in Ernexa Therapeutics Inc. by acquiring over 21 million shares, signaling strong confidence in the company's future.
• The acquisition was part of a private placement, indicating direct capital injection into the company.
• The private placement offering received stockholder approval, suggesting alignment with broader shareholder interests and corporate governance.
• The company paid a dividend to Series A Preferred Stock holders, demonstrating a commitment to providing returns to investors, even if in the form of common stock.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• The acquisition of shares by Charles Cherington, a Director and 10% owner, through a private placement can be considered a related party transaction.

Stakeholder Impact

• Shareholders: The private placement brings capital into the company, potentially strengthening its financial position, but also involves some dilution. The significant insider purchase may instill confidence in the company's prospects.
• Creditors: A capital raise can improve the company's balance sheet, potentially reducing credit risk.

Key Dates

Keywords

Ernexa Therapeutics Inc., ERNA, Charles Cherington, Form 4, SEC filing, insider trading, beneficial ownership, private placement, common stock, director, 10% owner, equity acquisition, stock dividend